| scholarly article | Q13442814 |
| P50 | author | Rodryg Ramlau | Q53373129 |
| P2093 | author name string | Dariusz Stencel | |
| Katarzyna Ramlau | |||
| Katarzyna Szyszka-Barth | |||
| P2860 | cites work | Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. | Q37338711 |
| Angiogenesis in the treatment of non-small cell lung cancer | Q37435385 | ||
| VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis | Q39959426 | ||
| Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer | Q42631933 | ||
| Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. | Q43138109 | ||
| Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer | Q43202368 | ||
| Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors | Q44175822 | ||
| Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study | Q59219589 | ||
| The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model | Q73704455 | ||
| The well-tempered vessel | Q73820249 | ||
| Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival | Q73853297 | ||
| High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression | Q77068395 | ||
| Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer | Q78054013 | ||
| Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study | Q80811673 | ||
| BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy | Q27650860 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| Angiogenesis: an organizing principle for drug discovery? | Q29614538 | ||
| Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors | Q29615445 | ||
| Mechanisms of angiogenesis and arteriogenesis | Q29617257 | ||
| Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid | Q29617640 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer | Q30422736 | ||
| Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. | Q33710753 | ||
| Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy | Q34157098 | ||
| Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy | Q34354300 | ||
| Angiogenesis and lung cancer: prognostic and therapeutic implications | Q34417759 | ||
| Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis | Q34578752 | ||
| Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. | Q34579127 | ||
| Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity | Q34580980 | ||
| Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. | Q34854658 | ||
| The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis | Q34859381 | ||
| Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib | Q35883400 | ||
| Molecular mechanisms of tumor vascularization. | Q36076261 | ||
| Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab | Q36084854 | ||
| Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing | Q36231924 | ||
| Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response? | Q36357248 | ||
| New antiangiogenetic agents and non-small cell lung cancer | Q36536999 | ||
| The potential of antiangiogenic therapy in non-small cell lung cancer. | Q36778505 | ||
| Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody | Q37051843 | ||
| The current status and evolving role of sunitinib in non-small cell lung cancer | Q37180214 | ||
| P433 | issue | 2 | |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | 145-150 | |
| P577 | publication date | 2014-06-29 | |
| P1433 | published in | Kardiochirurgia i Torakochirurgia Polska : kwartalnik Polskiego Towarzystwa Kardio-Torakochirurgów | Q26842278 |
| P1476 | title | Anti-angiogenic agents in the treatment of non-small cell lung cancer | |
| P478 | volume | 11 |
Search more.